Altered blood–brain barrier transport in neuro-inflammatory disorders

Drug Discovery Today: Technologies

Volumn 20, Issue , 2016, Pages 5-11

  Schenk, Geert J ^a   de Vries, Helga E ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALZHEIMER DISEASE; BLOOD BRAIN BARRIER; CELL INFILTRATION; CELL TRANSPORT; DRUG DELIVERY SYSTEM; DRUG TARGETING; ENDOCYTOSIS; GLIA CELL; HOMEOSTASIS; HUMAN; IMMUNOCOMPETENT CELL; MULTIPLE SCLEROSIS; NERVOUS SYSTEM INFLAMMATION; NEUROPROTECTION; NONHUMAN; REVIEW; CENTRAL NERVOUS SYSTEM DISEASES; INFLAMMATION; METABOLISM; TRANSPORT AT THE CELLULAR LEVEL;

BIOLOGICAL TRANSPORT; BLOOD-BRAIN BARRIER; CENTRAL NERVOUS SYSTEM DISEASES; HUMANS; INFLAMMATION;

EID: 85003837094     PISSN: None     EISSN: 17406749     Source Type: Journal    
DOI: 10.1016/j.ddtec.2016.07.002     Document Type: Review

References (89)

1. [1] Abbott, N.J., Astrocyte-endothelial interactions and blood-brain barrier permeability. J Anat 200 (2002), 629–638.
2. [2] Abbott, N.J., Ronnback, L., Hansson, E., Astrocyte-endothelial interactions at the blood-brain barrier. Nat Rev Neurosci 7 (2006), 41–53.
3. [3] Quan, N., Brain's firewall: blood-brain barrier actively regulates neuroimmune information flow. Brain Behav Immun 20 (2006), 447–448.
4. [4] Hawkins, B.T., Davis, T.P., The blood-brain barrier/neurovascular unit in health and disease. Pharmacol Rev 57 (2005), 173–185.
5. [5] Abbott, N.J., Romero, I.A., Transporting therapeutics across the blood-brain barrier. Mol Med Today 2 (1996), 106–113.
6. [6] DiNapoli, V.A., Huber, J.D., Houser, K., Li, X., Rosen, C.L., Early disruptions of the blood-brain barrier may contribute to exacerbated neuronal damage and prolonged functional recovery following stroke in aged rats. Neurobiol Aging 29 (2008), 753–764.
7. [7] Rip, J., Schenk, G.J., de Boer, A.G., Differential receptor-mediated drug targeting to the diseased brain. Expert Opin Drug Deliv 6 (2009), 227–237.
8. [8] Boado, R.J., Pardridge, W.M., The Trojan Horse Liposome Technology for Nonviral Gene Transfer across the Blood-Brain Barrier. J Drug Deliv, 2011, 2011, p296151.
9. [9] Friedman, A., Dingledine, R., Molecular cascades that mediate the influence of inflammation on epilepsy. Epilepsia 52:Suppl. 3 (2011), 33–39.
10. [10] Daneman, R., The blood-brain barrier in health and disease. Ann Neurol 72 (2012), 648–672.
11. [11] Erickson, M.A., Dohi, K., Banks, W.A., Neuroinflammation: a common pathway in CNS diseases as mediated at the blood-brain barrier. Neuroimmunomodulation 19 (2012), 121–130.
12. [12] Lopes Pinheiro, M.A., Kooij, G., Mizee, M.R., Kamermans, A., Enzmann, G., Lyck, R., et al. Immune cell trafficking across the barriers of the central nervous system in multiple sclerosis and stroke. Biochim Biophys Acta 1862 (2016), 461–471.
13. [13] Bell, R.D., Zlokovic, B.V., Neurovascular mechanisms and blood-brain barrier disorder in Alzheimer's disease. Acta Neuropathol 118 (2009), 103–113.
14. [14] Herholz, K., Weisenbach, S., Kalbe, E., Deficits of the cholinergic system in early AD. Neuropsychologia 46 (2008), 1642–1647.
15. [15] Kooi, E.J., Prins, M., Bajic, N., Belien, J.A., Gerritsen, W.H., van Horssen, J., et al. Cholinergic imbalance in the multiple sclerosis hippocampus. Acta Neuropathol 122 (2011), 313–322.
16. [16] Brousseau, G., Rourke, B.P., Burke, B., Acetylcholinesterase inhibitors, neuropsychiatric symptoms, and Alzheimer's disease subtypes: an alternate hypothesis to global cognitive enhancement. Exp Clin Psychopharmacol 15 (2007), 546–554.
17. [17] Kim, M.H., Maeng, H.J., Yu, K.H., Lee, K.R., Tsuruo, T., Kim, D.D., et al. Evidence of carrier-mediated transport in the penetration of donepezil into the rat brain. J Pharm Sci 99 (2010), 1548–1566.
18. [18] Ishiwata, K., Kawamura, K., Yanai, K., Hendrikse, N.H., In vivo evaluation of P-glycoprotein modulation of 8 PET radioligands used clinically. J Nucl Med 48 (2007), 81–87.
19. [19] Pochini, L., Scalise, M., Galluccio, M., Indiveri, C., OCTN cation transporters in health and disease: role as drug targets and assay development. J Biomol Screen 18 (2013), 851–867.
20. [20] Carrano, A., Hoozemans, J.J., van der Vies, S.M., Rozemuller, A.J., van Horssen, J., de Vries, H.E., Amyloid Beta induces oxidative stress-mediated blood-brain barrier changes in capillary amyloid angiopathy. Antioxid Redox Signal 15 (2011), 1167–1178.
21. [21] Carrano, A., Hoozemans, J.J., van der Vies, S.M., van Horssen, J., de Vries, H.E., Rozemuller, A.J., Neuroinflammation and blood-brain barrier changes in capillary amyloid angiopathy. Neurodegener Dis 10:1–4 (2012), 329–331.
22. [22] Richard, E., Carrano, A., Hoozemans, J.J., van Horssen, J., van Haastert, E.S., Eurelings, L.S., et al. Characteristics of dyshoric capillary cerebral amyloid angiopathy. J Neuropathol Exp Neurol 69:11 (2010), 1158–1167.
23. [23] de Boer, A.G., Gaillard, P.J., Drug targeting to the brain. Annu Rev Pharmacol Toxicol 47 (2007), 323–355.
24. [24] Lillis, A.P., Van Duyn, L.B., Murphy-Ullrich, J.E., Strickland, D.K., LDL receptor-related protein 1: unique tissue-specific functions revealed by selective gene knockout studies. Physiol Rev 88:3 (2008), 887–918.
25. [25] Deane, R., Wu, Z., Sagare, A., Davis, J., Du Yan, S., Hamm, K., et al. LRP/amyloid beta-peptide interaction mediates differential brain efflux of Abeta isoforms. Neuron 43:3 (2004), 333–344.
26. [26] Sagare, A., Deane, R., Bell, R.D., Johnson, B., Hamm, K., Pendu, R., et al. Clearance of amyloid-beta by circulating lipoprotein receptors. Nat Med 13:9 (2007), 1029–1031.
27. [27] Storck, S.E., Meister, S., Nahrath, J., Meissner, J.N., Schubert, N., Di Spiezio, A., et al. Endothelial LRP1 transports amyloid-beta1-42 across the blood-brain barrier. J Clin Invest 126:1 (2016), 123–136.
28. [28] Reale, M., Iarlori, C., Feliciani, C., Gambi, D., Peripheral chemokine receptors, their ligands, cytokines and Alzheimer's disease. J Alzheimers Dis 14:2 (2008), 147–159.
29. [29] Jaeger, L.B., Dohgu, S., Hwang, M.C., Farr, S.A., Murphy, M.P., Fleegal-DeMotta, M.A., et al. Testing the neurovascular hypothesis of Alzheimer's disease: LRP-1 antisense reduces blood-brain barrier clearance, increases brain levels of amyloid-beta protein, and impairs cognition. J Alzheimers Dis 17:3 (2009), 553–570.
30. [30] Jaeger, L.B., Dohgu, S., Sultana, R., Lynch, J.L., Owen, J.B., Erickson, M.A., et al. Lipopolysaccharide alters the blood-brain barrier transport of amyloid beta protein: a mechanism for inflammation in the progression of Alzheimer's disease. Brain Behav Immun 23:4 (2009), 507–517.
31. [31] Carrano, A., Snkhchyan, H., Kooij, G., van der Pol, S., van Horssen, J., Veerhuis, R., et al. ATP-binding cassette transporters P-glycoprotein and breast cancer related protein are reduced in capillary cerebral amyloid angiopathy. Neurobiol Aging 35:3 (2014), 565–575.
32. [32] Yu, Y.J., Atwal, J.K., Zhang, Y., Tong, R.K., Wildsmith, K.R., Tan, C., et al. Therapeutic bispecific antibodies cross the blood-brain barrier in nonhuman primates. Sci Transl Med, 6(261), 2014, 261ra154.
33. [33] Hartz, A.M., Bauer, B., Regulation of ABC transporters at the blood-brain barrier: new targets for CNS therapy. Mol Interv 10:5 (2010), 293–304.
34. [34] Alvarez, J.I., Cayrol, R., Prat, A., Disruption of central nervous system barriers in multiple sclerosis. Biochim Biophys Acta 1812:2 (2011), 252–264.
35. [35] Larochelle, C., Alvarez, J.I., Prat, A., How do immune cells overcome the blood-brain barrier in multiple sclerosis?. FEBS Lett 585:23 (2011), 3770–3780.
36. [36] Harris, J.O., Frank, J.A., Patronas, N., McFarlin, D.E., McFarland, H.F., Serial gadolinium-enhanced magnetic resonance imaging scans in patients with early, relapsing-remitting multiple sclerosis: implications for clinical trials and natural history. Ann Neurol 29:5 (1991), 548–555.
37. [37] Dutta, R., Trapp, B.D., Mechanisms of neuronal dysfunction and degeneration in multiple sclerosis. Prog Neurobiol 93:1 (2011), 1–12.
38. [38] Kirk, J., Plumb, J., Mirakhur, M., McQuaid, S., Tight junctional abnormality in multiple sclerosis white matter affects all calibres of vessel and is associated with blood-brain barrier leakage and active demyelination. J Pathol 201:2 (2003), 319–327.
39. [39] Kebir, H., Kreymborg, K., Ifergan, I., Dodelet-Devillers, A., Cayrol, R., Bernard, M., et al. Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation. Nat Med 13:10 (2007), 1173–1175.
40. [40] Cayrol, R., Wosik, K., Berard, J.L., Dodelet-Devillers, A., Ifergan, I., Kebir, H., et al. Activated leukocyte cell adhesion molecule promotes leukocyte trafficking into the central nervous system. Nat Immunol 9:2 (2008), 137–145.
41. [41] Leech, S., Kirk, J., Plumb, J., McQuaid, S., Persistent endothelial abnormalities and blood-brain barrier leak in primary and secondary progressive multiple sclerosis. Neuropathol Appl Neurobiol 33:1 (2007), 86–98.
42. [42] Kooij, G., Kroon, J., Paul, D., Reijerkerk, A., Geerts, D., van der Pol, S.M., et al. P-glycoprotein regulates trafficking of CD8(+) T cells to the brain parenchyma. Acta Neuropathol 127:5 (2014), 699–711.
43. [43] Kooij, G., Mizee, M.R., van Horssen, J., Reijerkerk, A., Witte, M.E., Drexhage, J.A., et al. Adenosine triphosphate-binding cassette transporters mediate chemokine (C–C motif) ligand 2 secretion from reactive astrocytes: relevance to multiple sclerosis pathogenesis. Brain 134:Pt 2 (2011), 555–570.
44. [44] Loma, I., Heyman, R., Multiple sclerosis: pathogenesis and treatment. Curr Neuropharmacol 9:3 (2011), 409–416.
45. [45] Lublin, F.D., Reingold, S.C., Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 46:4 (1996), 907–911.
46. [46] Compston, A., Coles, A., Multiple sclerosis. Lancet 372:9648 (2008), 1502–1517.
47. [47] Morrow, S.A., Metz, L.M., Kremenchutzky, M., High dose oral steroids commonly used to treat relapses in Canadian MS clinics. Can J Neurol Sci 36:2 (2009), 213–215.
48. [48] Cohen, B.A., Rivera, V.M., PRISMS: the story of a pivotal clinical trial series in multiple sclerosis. Curr Med Res Opin 26:4 (2010), 827–838.
49. [49] La Mantia, L., Munari, L.M., Lovati, R., Glatiramer acetate for multiple sclerosis. Cochrane Database Syst Rev(5), 2010, CD004678.
50. [50] Marriott, J.J., Miyasaki, J.M., Gronseth, G., O'Connor, P.W., Evidence Report: The efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 74:18 (2010), 1463–1470.
51. [51] Mellergard, J., Edstrom, M., Vrethem, M., Ernerudh, J., Dahle, C., Natalizumab treatment in multiple sclerosis: marked decline of chemokines and cytokines in cerebrospinal fluid. Mult Scler 16:2 (2010), 208–217.
52. [52] Sorensen, P.S., Blinkenberg, M., The potential role for ocrelizumab in the treatment of multiple sclerosis: current evidence and future prospects. Ther Adv Neurol Disord 9:1 (2016), 44–52.
53. [53] Abbott, N.J., Chugani, D.C., Zaharchuk, G., Rosen, B.R., Lo, E.H., Delivery of imaging agents into brain. Adv Drug Deliv Rev 37:1–3 (1999), 253–277.
54. [54] de Boer, A.G., van der Sandt, I.C., Gaillard, P.J., The role of drug transporters at the blood-brain barrier. Annu Rev Pharmacol Toxicol 43 (2003), 629–656.
55. [55] Gloor, S.M., Wachtel, M., Bolliger, M.F., Ishihara, H., Landmann, R., Frei, K., Molecular and cellular permeability control at the blood-brain barrier. Brain Res Brain Res Rev 36:2–3 (2001), 258–264.
56. [56] Dohgu, S., Yamauchi, A., Takata, F., Naito, M., Tsuruo, T., Higuchi, S., et al. Transforming growth factor-beta1 upregulates the tight junction and P-glycoprotein of brain microvascular endothelial cells. Cell Mol Neurobiol 24:3 (2004), 491–497.
57. [57] Deli, M.A., Descamps, L., Dehouck, M.P., Cecchelli, R., Joo, F., Abraham, C.S., et al. Exposure of tumor necrosis factor-alpha to luminal membrane of bovine brain capillary endothelial cells cocultured with astrocytes induces a delayed increase of permeability and cytoplasmic stress fiber formation of actin. J Neurosci Res 41:6 (1995), 717–726.
58. [58] Youakim, A., Ahdieh, M., Interferon-gamma decreases barrier function in T84 cells by reducing ZO-1 levels and disrupting apical actin. Am J Physiol 276:5 Pt 1 (1999), G1279–G1288.
59. [59] Tosi, G., Vilella, A., Veratti, P., Belletti, D., Pederzoli, F., Ruozi, B., et al. Exploiting Bacterial Pathways for BBB Crossing with PLGA Nanoparticles Modified with a Mutated Form of Diphtheria Toxin (CRM197): In Vivo Experiments. Mol Pharm 12:10 (2015), 3672–3684.
60. [60] Chiba, H., Osanai, M., Murata, M., Kojima, T., Sawada, N., Transmembrane proteins of tight junctions. Biochim Biophys Acta 1778:3 (2008), 588–600.
61. [61] Blasig, I.E., Haseloff, R.F., Tight junctions and tissue barriers. Antioxid Redox Signal 15:5 (2011), 1163–1166.
62. [62] Burke-Gaffney, A., Keenan, A.K., Modulation of human endothelial cell permeability by combinations of the cytokines interleukin-1 alpha/beta, tumor necrosis factor-alpha and interferon-gamma. Immunopharmacology 25:1 (1993), 1–9.
63. [63] Wojciak-Stothard, B., Entwistle, A., Garg, R., Ridley, A.J., Regulation of TNF-alpha-induced reorganization of the actin cytoskeleton and cell-cell junctions by Rho. Rac, and Cdc42 in human endothelial cells. J Cell Physiol 176:1 (1998), 150–165.
64. [64] Utech, M., Ivanov, A.I., Samarin, S.N., Bruewer, M., Turner, J.R., Mrsny, R.J., et al. Mechanism of IFN-gamma-induced endocytosis of tight junction proteins: myosin II-dependent vacuolarization of the apical plasma membrane. Mol Biol Cell 16:10 (2005), 5040–5052.
65. [65] Kumagai, A.K., Eisenberg, J.B., Pardridge, W.M., Absorptive-mediated endocytosis of cationized albumin and a beta-endorphin-cationized albumin chimeric peptide by isolated brain capillaries. Model system of blood-brain barrier transport. J Biol Chem 262:31 (1987), 15214–15219.
66. [66] Pardridge, W.M., Kumagai, A.K., Eisenberg, J.B., Chimeric peptides as a vehicle for peptide pharmaceutical delivery through the blood-brain barrier. Biochem Biophys Res Commun 146:1 (1987), 307–313.
67. [67] Drin, G., Cottin, S., Blanc, E., Rees, A.R., Temsamani, J., Studies on the internalization mechanism of cationic cell-penetrating peptides. J Biol Chem 278:33 (2003), 31192–31201.
68. [68] Lossinsky, A.S., Shivers, R.R., Structural pathways for macromolecular and cellular transport across the blood-brain barrier during inflammatory conditions. Review. Histol Histopathol 19:2 (2004), 535–564.
69. [69] Kumar, P., Wu, H., McBride, J.L., Jung, K.E., Kim, M.H., Davidson, B.L., et al. Transvascular delivery of small interfering RNA to the central nervous system. Nature 448:7149 (2007), 39–43.
70. [70] Duchini, A., Govindarajan, S., Santucci, M., Zampi, G., Hofman, F.M., Effects of tumor necrosis factor-alpha and interleukin-6 on fluid-phase permeability and ammonia diffusion in CNS-derived endothelial cells. J Investig Med 44:8 (1996), 474–482.
71. [71] Banks, W.A., Kastin, A.J., Brennan, J.M., Vallance, K.L., Adsorptive endocytosis of HIV-1gp120 by blood-brain barrier is enhanced by lipopolysaccharide. Exp Neurol 156:1 (1999), 165–171.
72. [72] Cipolla, M.J., Crete, R., Vitullo, L., Rix, R.D., Transcellular transport as a mechanism of blood-brain barrier disruption during stroke. Front Biosci 9 (2004), 777–785.
73. [73] Wong, H.L., Wu, X.Y., Bendayan, R., Nanotechnological advances for the delivery of CNS therapeutics. Adv Drug Deliv Rev, 2012.
74. [74] Reichel, A., Begley, D.J., Abbott, N.J., Carrier-mediated delivery of metabotrophic glutamate receptor ligands to the central nervous system: structural tolerance and potential of the L-system amino acid transporter at the blood-brain barrier. J Cereb Blood Flow Metab 20:1 (2000), 168–174.
75. [75] Chishty, M., Reichel, A., Siva, J., Abbott, N.J., Begley, D.J., Affinity for the P-glycoprotein efflux pump at the blood-brain barrier may explain the lack of CNS side-effects of modern antihistamines. J Drug Target 9:3 (2001), 223–228.
76. [76] Abbott, N.J., Patabendige, A.A., Dolman, D.E., Yusof, S.R., Begley, D.J., Structure and function of the blood-brain barrier. Neurobiol Dis 37:1 (2010), 13–25.
77. [77] Pardridge, W.M., Eisenberg, J., Yang, J., Human blood-brain barrier transferrin receptor. Metabolism 36:9 (1987), 892–895.
78. [78] Shin, S.U., Friden, P., Moran, M., Olson, T., Kang, Y.S., Pardridge, W.M., et al. Transferrin-antibody fusion proteins are effective in brain targeting. Proc Natl Acad Sci U S A 92:7 (1995), 2820–2824.
79. [79] Lee, H.J., Engelhardt, B., Lesley, J., Bickel, U., Pardridge, W.M., Targeting rat anti-mouse transferrin receptor monoclonal antibodies through blood–brain barrier in mouse. J Pharmacol Exp Ther 292:3 (2000), 1048–1052.
80. [80] Harel, E., Rubinstein, A., Nissan, A., Khazanov, E., Nadler Milbauer, M., Barenholz, Y., et al. Enhanced transferrin receptor expression by proinflammatory cytokines in enterocytes as a means for local delivery of drugs to inflamed gut mucosa. PLoS One, 6(9), 2011, e24202.
81. [81] Gaillard, P.J., Visser, C.C., de Boer, A.G., Targeted delivery across the blood-brain barrier. Expert Opin Drug Deliv 2:2 (2005), 299–309.
82. [82] Gaillard, P.J., de Boer, A.G., A novel opportunity for targeted drug delivery to the brain. J Control Release 116:2 (2006), pe60–pe62.
83. [83] Wang, P., Liu, Y., Shang, X., Xue, Y., CRM197-induced blood-brain barrier permeability increase is mediated by upregulation of caveolin-1 protein. J Mol Neurosci 43:3 (2011), 485–492.
84. [84] Schenk, G.J., Dijkstra, S., van het Hof, A.J., van der Pol, S.M., Drexhage, J.A., van der Valk, P., et al. Roles for HB-EGF and CD9 in multiple sclerosis. Glia 61:11 (2013), 1890–1905.
85. [85] Schenk, G.J., Haasnoot, P.C., Centlivre, M., Legrand, N., Rip, J., de Boer, A.G., et al. Efficient CRM197-mediated drug targeting to monocytes. J Control Release 158:1 (2012), 139–147.
86. [86] Begley, D.J., ABC transporters and the blood-brain barrier. Curr Pharm Des 10:12 (2004), 1295–1312.
87. [87] Banks, W.A., Erickson, M.A., The blood-brain barrier and immune function and dysfunction. Neurobiol Dis 37:1 (2010), 26–32.
88. [88] van Rooy, I., Hennink, W.E., Storm, G., Schiffelers, R.M., Mastrobattista, E., Attaching the phage display-selected GLA peptide to liposomes: factors influencing target binding. Eur J Pharm Sci 45:3 (2012), 330–335.
89. [89] Banks, W.A., Blood-brain barrier as a regulatory interface. Forum Nutr 63 (2010), 102–110.